Bausch and Lomb Newswire (Page 2)

Bausch and Lomb Newswire (Page 2)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 2)

Results 21 - 40 of 661 in Bausch and Lomb

  1. Europe Eye Care Surgical Market 2021: Industrial Forecast and TrendsRead the original story

    Friday Jul 8 | Emailwire.com

    The Europe Eye Care Surgical Industry 2016-2021 Market Research Report is a professional and in-depth study on the current state of the Eye Care Surgical industry. The report provides a basic overview of the industry including definitions, classifications 'Europe Eye Care Surgical Industry 2016 Market Research Report' Order This Report by calling ResearchnReports.com at +1-888-631-6977.

    Comment?

  2. Valeant Is 'The Walking Dead'Read the original story w/Photo

    Thursday Jul 7 | TheStreet.com

    The troubled drugmaker will have to perform a careful balancing act it begins to unwind some of its businesses to shore up cash. The troubled Canadian drugmaker -- which is now being forced to walk back on its former debt-fueled strategy of snapping up companies and subsequently hiking prices on acquired drugs -- will have to perform a careful balancing act it begins to unwind some of its businesses to shore up cash.

    Comment?

  3. Valeant 'The Walking Dead' - Andrew LeftRead the original story w/Photo

    Thursday Jul 7 | Seeking Alpha

    "If they sell a business for significantly less than what they purchased, the company could completely implode," says Citron's Andrew Left . "People have no confidence in the business model and it shows in the stock price.

    Comment?

  4. Why Valeant Pharmaceuticals, Nortek, and SUPERVALU Jumped TodayRead the original story w/Photo

    Wednesday Jul 6 | Fox News

    Wednesday showed the resiliency of the stock market in a way that investors have seen countless times during the seven-year-old bull market. Major market benchmarks started the day with substantial declines, and the Dow fell more than 125 points by mid-morning as investors feared further fallout from macroeconomic and geopolitical events.

    Comment?

  5. Bausch & Lomb And Announce The Publication Of Latanoprostene Bunod...Read the original story

    Tuesday Jul 5 | BioSpace

    Bausch & Lomb And Nicox Announce The Publication Of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results In American Journal Of Ophthalmology /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology . LBN 0.024% is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle glaucoma or ocular hypertension .

    Comment?

  6. Bausch + Lomb and Nicox Announce the Publication of Latanoprostene...Read the original story

    Wednesday Jul 6 | P&T Community

    Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology . LBN 0.024% is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle glaucoma or ocular hypertension .

    Comment?

  7. Valeant Pharmaceuticals International, Inc.Read the original story w/Photo

    Apr 15, 2016 | PR Newswire

    Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology . LBN 0.024% is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle glaucoma or ocular hypertension .

    Comment?

  8. Valeant Has Bottomed but Don't Even Think of Buying YetRead the original story w/Photo

    Tuesday Jul 5 | TheStreet.com

    Shares of beleagured drug maker Valeant Pharmaceuticals have plunged more than 17%, falling from $22.42 per share to a recent 52-week low of $18.55 since I recommended the stock as a solid short candidate on June 17. At the time Valeant's chart pointed to lower lows, suggesting towards $20 or below was its next level of support. That's what happened.

    Comment?

  9. Bausch & Lomb Incorporated - Product Pipeline Analysis, 2016 Update - New Market Research ReportRead the original story w/Photo

    Monday Jul 4 | PR-inside.com

    Bausch & Lomb Incorporated , a subsidiary of Valeant Pharmaceuticals International, Inc., is a global healthcare company. It develops, manufactures and markets eye health products for a wide range of eye conditions including glaucoma, conjunctivitis, eye allergies, dry eye and retinal diseases.

    Comment?

  10. Walgreens Boots Alliance (WBA) Stock Down Ahead of Q3 EarningsRead the original story w/Photo

    Friday Jul 1 | TheStreet.com

    Walgreens Boots Alliance stock is declining 1.15% to $83.14 in afternoon trading on Friday ahead of the retail pharmacy chain's fiscal 2016 third quarter financial report, due out on Wednesday before the opening bell. The Deerfield, IL-based company is expected to deliver a year-over-year increase in earnings per share and revenue.

    Comment?

  11. QYResearch: Industry Analysis Report for United States Femtosecond Laser Industry 2016Read the original story w/Photo

    Thursday Jun 30 | PR-inside.com

    Note:We also offer Malaysia/Saudi Arabia/Middle East/Europe/Asia/Asia-Pacific/Southeast Asia/North America/ Latin America/South America/AMER/EMEA/Africa etc Countries/Regions and Sales/Consumption Versions Respectively Short description United States Femtosecond Laser Industry 2016 Market Research Report is a new market report published by QYResearch. This report is a professional and in-depth study on the current state of the Femtosecond Laser industry.

    Comment?

  12. Valeant Is Cash-Poor, and Even Bausch & Lomb Division May Not Save ItRead the original story w/Photo

    Wednesday Jun 29 | TheStreet.com

    The drugmaker could risk violating debt covenants, even if it fetches up to $8 billion for the eye-care giant. After more than 90% of Valeant Pharmaceuticals' market cap vanished following last summer's highs, all eyes are now on how much the struggling drugmaker could fetch by selling assets to cope with its $31 billion debt stack.

    Comment?

  13. Valeant Needs Cash and 'Crown Jewel' Bausch & Lomb May Be Losing ValueRead the original story

    Wednesday Jun 29 | TheStreet.com

    After more than 90% of Valeant Pharmaceutical 's market cap vanished following last summer's highs, all eyes are now on how much the struggling drugmaker could fetch by selling assets to cope with its $31 billion debt stack. Bill Ackman, the billionaire activist who recently took a seat on Valeant's board, recently said the company has no plan to sell core, so-called "crown jewel" assets, notably eye-care giant Bausch & Lomb.

    Comment?

  14. The 2 Big Reasons Valeant Pharmaceuticals Intl. Inc., Shares Are Down 80% in 2016Read the original story w/Photo

    Wednesday Jun 29 | The Motley Fool

    The source of Valeant's woes can be traced to two big concerns. So what: The first issue plaguing Valeant is the multiple probes into its pricing practices.

    Comment?

  15. Infectious Disease Treatment Market in China to Grow at a CAGR of...Read the original story w/Photo

    Jun 28, 2016 | SBWire

    Report forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020. Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses.

    Comment?

  16. In This Edition...Read the original story w/Photo

    Jun 28, 2016 | Vision Monday

    Quick Take: Armourx has announced the Realtree by Armourx safety eyewear collection that strikes a balance between practicality and style, the company said. Wearer: Designed for men and women in the workplace.

    Comment?

  17. And the winners of our first-ever Meetup and Pitch-Off in Tel Aviv area .Read the original story w/Photo

    Jun 22, 2016 | TechCrunch

    You are about to activate our Facebook Messenger news bot. Once subscribed, the bot will send you a digest of trending stories once a day.

    Comment?

  18. The spooky skeleton of BryceRead the original story w/Photo

    Jun 21, 2016 | Alabama Live

    ... the university but he said a number of additional artifacts were found during demolition, including a 1915 Bausch and Lomb microscope that was marked as property of Dr. James Searcy, Peter Bryce's successor. Davis has also preserved an autoclave for ...

    Comment?

  19. Stan Henson. Jr. releases new Jazz projectRead the original story w/Photo

    Jun 20, 2016 | PR Log

    ... for Motown and Universal Music. Henson went on to compose music for television commercials that include Bausch and Lomb and TV shows such as Santa Barbara. While attending college, Henson studied music and acting. He interned at RCA/BMG Music in ...

    Comment?

  20. How Much Is Valeant Pharmaceuticals Really Worth?Read the original story w/Photo

    Jun 17, 2016 | The Motley Fool

    Valeant Pharmaceuticals has seen its market valuation shrink from a peak of around $90 billion in August to just $7.7 billion as of Thursday's closing price, marking yet another fresh 52-week low. First, the company's business model is in jeopardy.

    Comment?